Next 10 |
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Ebvallo is the First and Only Approved Therapy in Europe for Adults and Children with EBV+ PTLD Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies ...
2024-06-20 09:02:05 ET Atara Biotherapeutics Inc (ATRA) announced stock split at a ratio of 1-for-25 on 2024-06-20 ... Full story available on KlickAnalytics.com
2024-06-17 08:24:32 ET More on Atara Biotherapeutics Seeking Alpha’s Quant Rating on Atara Biotherapeutics Historical earnings data for Atara Biotherapeutics Financial information for Atara Biotherapeutics Read the full article on Seeking Alpha ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it will conduct a reverse stock split...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
ATA3219 Demonstrates Complete CD19-Specific B-Cell Depletion Against Systemic Lupus Erythematosus and Multiple Sclerosis Patient Peripheral Blood Mononuclear Cells ATA3219 Induces Lower Levels of Pro-Inflammatory Cytokines While Maintaining Cytotoxic Potency Compared With Autologous Bench...
First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD Acceptance of BLA Will Trigger $20 Million Milestone Payment from Pierre Fabre Laboratories, with Potential for Additional...
2024-05-09 17:26:54 ET More on Atara Biotherapeutics FDA clears Atara to begin Phase 1 study for lupus nephritis drug Baupost Group steps away from Atara, Veritiv; bulks up on Clarivate, Jazz Pharma Seeking Alpha’s Quant Rating on Atara Biotherapeutics ...
Tab-cel ® U.S. BLA on Track for Submission in Q2 2024 Initiation of ATA3219 Lupus Nephritis Study Expected in Q4 2024, with Initial Clinical Data Expected in H1 2025 Initiation of New ATA3219 Cohort Without Lymphodepletion in Severe Systemic Lupus Erythematosus Planned fo...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Ebvallo is the First and Only Approved Therapy in Europe for Adults and Children with EBV+ PTLD Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies ...
2024-06-20 09:02:05 ET Atara Biotherapeutics Inc (ATRA) announced stock split at a ratio of 1-for-25 on 2024-06-20 ... Full story available on KlickAnalytics.com